K36 Therapeutics Unveils KTX-2001 Prostate Cancer Study Design
24 Feb 2026 //
PR NEWSWIRE
K36 Therapeutics Completes KTX-2001 Dosing for Prostate Cancer
05 Feb 2026 //
PR NEWSWIRE
K36 Therapeutics Presents First Human Data On Gintemetostat
05 Dec 2025 //
PR NEWSWIRE
K36 Therapeutics Showcases Preclinical Data for KTX-1001 Phase 1
18 Sep 2025 //
PR NEWSWIRE
FDA clears K36 Therapeutics` IND for KTX-2001 in mCRPC Cancer
08 Aug 2025 //
PR NEWSWIRE
K36 Therapeutics Announces Appointment of Benjamin Winograd as CMO
15 Nov 2023 //
PR NEWSWIRE
K36 Therapeutics raises $70M in Series B to fund multiple myeloma research
28 Jun 2023 //
ENDPTS

Market Place
Sourcing Support